Skip to content

Carpenter Technology

US · CRS #951 by market cap Listed 1970
254.00 -13.84 -5.17%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Recent news

  • SIG Maintains Carpenter Technology(CRS.US) With Buy Rating, Cuts Target Price to $450
    \u5e02\u573a\u8d44\u8baf · 2026/10/23
  • Rating change
    KeyBanc Maintains Carpenter Technology(CRS.US) With Buy Rating, Cuts Target Price to $608
    \u5e02\u573a\u8d44\u8baf · 2026/8/4
  • Rating change
    TD Cowen Maintains Carpenter Technology(CRS.US) With Buy Rating, Cuts Target Price to $500
    \u5e02\u573a\u8d44\u8baf · 2026/10/9
  • Company notice
    ULTIMATE HLDGS GROUP INC | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-CRS Consulting, LLC(1.00%),Thomas DeNunzio(0.33%), etc.
    SEC · 2023/4/27
  • Company notice
    BLUBUZZARD INC | SC 13D: Statement of acquisition of beneficial ownership by individuals-CRS Consulting, LLC(72.25%),Thomas DeNunzio(24.08%), etc.
    SEC · 2024/6/13
  • Rating change
    KeyBanc Maintains Carpenter Technology(CRS.US) With Buy Rating, Cuts Target Price to $465
    \u5e02\u573a\u8d44\u8baf · 2026/10/8
  • J.P. Morgan Maintains Carpenter Technology(CRS.US) With Buy Rating, Cuts Target Price to $520
    \u5e02\u573a\u8d44\u8baf · 2026/10/14
  • Company notice
    AnPac Bio-Medical Science | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-CRS Holdings Inc.(0.06%),Chris Chang Yu(0.06%)
    SEC · 2022/10/13
  • Company notice
    ULTIMATE HLDGS GROUP INC | SC 13D: Statement of acquisition of beneficial ownership by individuals-CRS Consulting, LLC(81.75%),Thomas DeNunzio(27.25%), etc.
    SEC · 2022/12/1
  • Rating change
    Deutsche Bank Maintains Carpenter Technology(CRS.US) With Buy Rating, Raises Target Price to $689
    \u5e02\u573a\u8d44\u8baf · 2026/7/31
  • SIG Maintains Carpenter Technology(CRS.US) With Buy Rating, Maintains Target Price $450
    \u5e02\u573a\u8d44\u8baf · 2026/11/20
  • BTIG Maintains Carpenter Technology(CRS.US) With Buy Rating, Cuts Target Price to $470
    \u5e02\u573a\u8d44\u8baf · 2026/10/23
  • Rating change
    J.P. Morgan Maintains Carpenter Technology(CRS.US) With Buy Rating, Maintains Target Price $700
    \u5e02\u573a\u8d44\u8baf · 2026/8/5
  • Rating change
    Wells Fargo Maintains Carpenter Technology(CRS.US) With Hold Rating, Raises Target Price to $430
    \u5e02\u573a\u8d44\u8baf · 2026/9/30
  • Rating change
    BTIG Maintains Carpenter Technology(CRS.US) With Buy Rating, Raises Target Price to $620
    \u5e02\u573a\u8d44\u8baf · 2026/7/31
  • Rating change
    SIG Maintains Carpenter Technology(CRS.US) With Buy Rating, Maintains Target Price $600
    \u5e02\u573a\u8d44\u8baf · 2026/10/7
  • Company notice
    AnPac Bio-Medical Science | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-CRS Holdings Inc.(0.06%),Chris Chang Yu(0.06%)
    SEC · 2022/10/13
  • KeyBanc Downgrades Carpenter Technology(CRS.US) to Hold Rating
    \u5e02\u573a\u8d44\u8baf · 2026/10/26
  • Rating change
    J.P. Morgan Maintains Carpenter Technology(CRS.US) With Buy Rating, Raises Target Price to $700
    \u5e02\u573a\u8d44\u8baf · 2026/7/31
  • Rating change
    SIG Maintains Carpenter Technology(CRS.US) With Buy Rating, Cuts Target Price to $600
    \u5e02\u573a\u8d44\u8baf · 2026/7/31
  • Rating change
    J.P. Morgan Maintains Carpenter Technology(CRS.US) With Buy Rating, Raises Target Price to $705
    \u5e02\u573a\u8d44\u8baf · 2026/7/14
  • Rating change
    TD Cowen Maintains Carpenter Technology(CRS.US) With Buy Rating, Raises Target Price to $650
    \u5e02\u573a\u8d44\u8baf · 2026/7/13
  • Rating change
    SIG Maintains Carpenter Technology(CRS.US) With Buy Rating, Raises Target Price to $680
    \u5e02\u573a\u8d44\u8baf · 2026/7/9
  • Rating change
    J.P. Morgan Remains a Buy on Carpenter Technology (CRS)
    TipRanks · 2026/7/13
  • Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No...
    Benzinga · 2026/9/28

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:01:08 · For reference only, not investment advice and not tailored to your situation.

Carpenter Technology discussion 0 comments

Add a comment